Radiomics-based Models for the Prediction of Pathological Response to Neoadjuvant Therapy in Gastric and Gastroesophageal Cancer

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06044961

Acronym

RADI-S

Enrollment

Registered

2023-09-21

Start date

2005-01-01

Completion date

2022-11-15

Last updated

2023-09-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients With Locally Advanced Carcinoma of the Stomach and Oesophagogastric Junction

Keywords

stomach cancer, esophagogastric junction., locally advanced carcinoma of the stomach, radiomics

Brief summary

Identifying predictors of response to neoadjuvant therapy in gastric and gastro-oesophageal cancer early in the history of the disease would ensure optimal treatment planning. The study aims to apply radiomics for the prediction of response to neoadjuvant therapy.

Interventions

RADIATIONCT scan

All pre-operative CT scan collected

Study design

Observational model

OTHER

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* Patients with locally advanced stomach cancer undergoing neoadjuvant chemotherapy and gastrectomy between January 2005 and August 2022

Exclusion criteria

* Siewert 1 tumors; * Patients who have received neoadjuvant with the addition of a biological drug; * Patients who have received radiotherapy; * Patients without staging CT scan or with insufficient image quality in terms of phases performed, pixel spacing, slide thickness (mandatorily: \> 5 mm) or artefacts.

Design outcomes

Primary

Measure	Time frame	Description
Use of radiomics	1 month	Apply radiomics for predicting response to neoadjuvant therapy.

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026